Literature DB >> 25329640

Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care.

G V Ramos1, L Guaraldo, A M Japiassú, F A Bozza.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Adverse drug events (ADE), common and underestimated in ICU patients, have direct consequences on length of stay, mortality and hospital costs. Critically ill patients with HIV/AIDS are at a high risk of ADE because of their need for multiple drug therapies. ADE can be prevented, especially by the identification of potentially harmful drug-drug interactions (DDIs). Electronic databases are useful tools for the investigation of DDIs to avoid potential ADEs, thereby increasing patient safety. The purpose of this study was to compare the classification and severity rating of potential adverse drug interactions seen in the prescriptions for patients with HIV/AIDS in two databases, one with free access (Drugs.com(™)) and another requiring payment for access (Micromedex(®)).
METHODS: A cross-sectional retrospective study of the prescriptions issued for 40 ICU HIV/AIDS patients on mechanical ventilation, admitted for more than 48 h, in a referral hospital for infectious diseases in Rio de Janeiro, Brazil, was undertaken. One prescription was reviewed each week for each patient from the second day after admission. A list of all drug-drug interactions was generated for each patient using the two drug-drug interactions databases. The weighted kappa index was estimated to assess the agreement between the classifications of DDIs identified by both databases and qualitative assessment made of any discordant classification of recorded drug-drug interactions. RESULTS AND DISCUSSION: Of the 106 prescriptions analysed, Micromedex(®) and Drugs.com identified 347 and 615 potential DDIs, respectively. A predominance of moderate interactions and pharmacokinetic interactions was observed. The agreement between the databases regarding the severity rating was only 68.3%. The weighted kappa of 0.44 is considered moderate. Better agreement (82.4%) was observed in the classification of mechanism of interaction, with a weighted kappa of 0.61. WHAT IS NEW AND
CONCLUSION: DDIs are common between the prescriptions of patients with HIV/AIDS admitted to the ICU. Although both databases were able to identify the clinically relevant DDIs, we observed a significant discrepancy in the classification of the severity of DDIs in the two bases. The free access database could serve as an alternative to the identification of DDIs in resource-limited settings; however, there is a need for better evidence-based assessments for your use on clinical management of more serious DDIs.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  AIDS; critically ill; drug prescriptions; drug-drug interactions; intensive care unit; pharmacovigilance

Mesh:

Substances:

Year:  2014        PMID: 25329640     DOI: 10.1111/jcpt.12222

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  11 in total

1.  Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study.

Authors:  Neža Muhič; Ales Mrhar; Miran Brvar
Journal:  Eur J Clin Pharmacol       Date:  2017-03-15       Impact factor: 2.953

2.  Prevalence and nature of potential drug-drug interactions among kidney transplant patients in a German intensive care unit.

Authors:  Julia Amkreutz; Alexander Koch; Lukas Buendgens; Anja Muehlfeld; Christian Trautwein; Albrecht Eisert
Journal:  Int J Clin Pharm       Date:  2017-08-19

3.  Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining.

Authors:  Camille Morival; Richard Westerlynck; Guillaume Bouzillé; Marc Cuggia; Pascal Le Corre
Journal:  Eur J Clin Pharmacol       Date:  2017-12-18       Impact factor: 2.953

Review 4.  Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis.

Authors:  Mary Grace Fitzmaurice; Adrian Wong; Hannah Akerberg; Simona Avramovska; Pamela L Smithburger; Mitchell S Buckley; Sandra L Kane-Gill
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

Review 5.  Highly active antiretroviral therapy for critically ill HIV patients: A systematic review and meta-analysis.

Authors:  Hugo Boechat Andrade; Cassia Righy Shinotsuka; Ivan Rocha Ferreira da Silva; Camila Sunaitis Donini; Ho Yeh Li; Frederico Bruzzi de Carvalho; Pedro Emmanuel Alvarenga Americano do Brasil; Fernando Augusto Bozza; Andre Miguel Japiassu
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

6.  Preventable adverse drug events in critically ill HIV patients: Is the detection of potential drug-drug interactions a useful tool?

Authors:  Grazielle Viana Ramos; André Miguel Japiassú; Fernando Augusto Bozza; Lusiele Guaraldo
Journal:  Clinics (Sao Paulo)       Date:  2018-02-19       Impact factor: 2.365

7.  Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases.

Authors:  Bovornpat Suriyapakorn; Pun Chairat; Suwanan Boonyoprakarn; Pimonwan Rojanarattanangkul; Wassana Pisetcheep; Natthaphon Hunsakunachai; Pornpun Vivithanaporn; Supakit Wongwiwatthananukit; Phisit Khemawoot
Journal:  PLoS One       Date:  2019-11-14       Impact factor: 3.240

8.  Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases.

Authors:  Pornpun Vivithanaporn; Teetat Kongratanapasert; Bovornpat Suriyapakorn; Pichayut Songkunlertchai; Patpicha Mongkonariyawong; Patanachai K Limpikirati; Phisit Khemawoot
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

9.  Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital.

Authors:  Rizky Abdulah; Tazkia F Suwandiman; Nadhira Handayani; Dika P Destiani; Auliya A Suwantika; Melisa I Barliana; Keri Lestari
Journal:  Ther Clin Risk Manag       Date:  2017-07-21       Impact factor: 2.423

10.  Variation in high-priority drug-drug interaction alerts across institutions and electronic health records.

Authors:  Dustin S McEvoy; Dean F Sittig; Thu-Trang Hickman; Skye Aaron; Angela Ai; Mary Amato; David W Bauer; Gregory M Fraser; Jeremy Harper; Angela Kennemer; Michael A Krall; Christoph U Lehmann; Sameer Malhotra; Daniel R Murphy; Brandi O'Kelley; Lipika Samal; Richard Schreiber; Hardeep Singh; Eric J Thomas; Carl V Vartian; Jennifer Westmorland; Allison B McCoy; Adam Wright
Journal:  J Am Med Inform Assoc       Date:  2017-03-01       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.